Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q86U90

UPID:
YRDC_HUMAN

ALTERNATIVE NAMES:
Dopamine receptor-interacting protein 3; Ischemia/reperfusion-inducible protein homolog

ALTERNATIVE UPACC:
Q86U90; Q4W4X8; Q6NVW3; Q7L4E4; Q7Z2I4; Q9H5F8

BACKGROUND:
Threonylcarbamoyl-AMP synthase functions in the critical modification of tRNAs, facilitating the accurate decoding of mRNA codons. This enzyme's activity is pivotal for protein synthesis across cytoplasmic and mitochondrial environments, highlighting its universal importance in cellular biology. It is known by alternative names such as Dopamine receptor-interacting protein 3 and Ischemia/reperfusion-inducible protein homolog.

THERAPEUTIC SIGNIFICANCE:
Given its association with Galloway-Mowat syndrome 10, a disorder marked by significant renal and neurological manifestations, Threonylcarbamoyl-AMP synthase represents a promising target for therapeutic intervention. The exploration of its function and mechanisms offers a pathway to novel treatments for this devastating disease, underscoring the therapeutic potential of this protein.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.